The Top 5 Biosimilars Articles for the Week of October 2

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of October 2.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of October 2.

Number 5: Medicines for Europe has released a new report, prepared by the Economist Intelligence Unit, that attempts to address the problem of medicines shortages in Europe.

Number 4: FDA Commissioner, Dr Scott Gottlieb, announced 2 new initiatives this week. One is aimed at increasing competition for complex generics, and the other streamlines the process for patients to receive investigational drugs for compassionate use.

Number 3: In a new report on drug spending, pharmacy benefit manager Express Scripts says that a group comprising less than 1% of US patients accounts for more than 20% of total pharmacy spending.

Number 2: Allergan is being sued by fellow Irish drug maker, Shire, over its embattled dry eye drug, Restasis.

Number 1: A newly published case report suggests that biosimilar infliximab could present a new treatment option for patients with HIV who develop mycobacterial immune reconstitution inflammatory syndrome.

Finally, last week, our newsletter asked for your input on how suffixes to biosimilars’ names should be addressed. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.